Novo Nordisk
2011-09-29T20:02:50Z
2011-09-29T20:02:50Z
Novo Nordisk files for regulatory approval of the ultra-long-acting insulins Degludec and DegludecPlus in the US
Novo Nordisk today announced the submission to the US Food and Drug Administration of two new drug applications for the approval of ultra-long-acting insulin Degludec and the insulin combination analogue DegludecPlus, respectively. This new generation of insulins has been developed for the treatment of people with type 1 and type 2 diabetes.
Further information:
Media: | Investors: |
| Katrine Sperling | Klaus Bülow Davidsen |
| Tel: (+45) 4442 6718 | Tel: (+45) 4442 3176 |
| krsp@novonordisk.com | klda@novonordisk.com |
| Frank Daniel Mersebach | |
| Tel: (+45) 4442 0604 | |
| fdni@novonordisk.com | |
| Lars Borup Jacobsen | |
| Tel: (+45) 3075 3479 | |
| lbpj@novonordisk.com | |
| In North America: | |
| Ambre Morley | Jannick Lindegaard |
| Tel: (+1) 609 216 5240 | Tel: (+1) 609 786 4575 |
| abmo@novonordisk.com | jlis@novonordisk.com |
Company Announcement no 61 / 2011